Battle of the British PARPs at ESMO 2019

28 September 2019

At the annual congress of the European Society of Medical Oncology (ESMO) in Barcelona, Spain, rival datasets for Lynparza (olaparib) and Zejula (niraparib) have teed up a competition between UK-based drugmakers AstraZeneca (LSE: AZN) and GlaxoSmithKline (LSE: GSK).

AstraZeneca has thus far led the way in the growing field of PARP inhibition, with a recent approval in ovarian cancer adding a third indication and second tumor type, after breast cancer, to the label.

But, while early research suggested the main value of PARP blockers would be in treating BRCA positive cancers, Zejula developer Tesaro was quick to discover the potential for a broader population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK